Checkpoint inhibitor response prediction milestone using patient-derived ex vivo spheroids

Greenville, SC – March 11, 2021 – KIYATEC, Inc researchers demonstrated that their immune-modified ex vivo platform can measure treatment response through direct interaction between a patient’s cancer and infiltrating immune cells, and immuno-oncology agents. This work, published in the March 2021 issue of Cancer Immunology, Immunotherapy, validates the use of this platform in a…

Details